Clinical exacerbation of SARS-CoV2 infection after fingolimod withdrawal.
COVID-19
SARS-CoV-2
coronavirus
exacerbation
fingolimod
multiple sclerosis
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
16
06
2020
revised:
05
07
2020
accepted:
06
07
2020
pubmed:
10
7
2020
medline:
10
3
2021
entrez:
10
7
2020
Statut:
ppublish
Résumé
The role of disease-modifying therapies in patients with autoimmune disorders during severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection is controversial. Immunocompromised patients could have a more severe coronavirus disease-2019 (COVID-19) due to the absence of an adequate immune response against the SARS-CoV-2. However, therapies that act on immune response could play a protective role by dampening the cytokine-release syndrome. Fingolimod is a drug used for immune therapy in patients with multiple sclerosis (MS) through the sequestration of activated lymphocytes in the lymph nodes. We report the case of a 57-year-old man with relapsing-remitting MS treated with fingolimod that showed a reactivation of COVID-19 with signs of hyperinflammation syndrome after fingolimod withdrawal. Our case suggests that discontinuation of fingolimod during COVID-19 could imply a worsening of SARS-CoV2 infection.
Identifiants
pubmed: 32644205
doi: 10.1002/jmv.26279
pmc: PMC7361541
doi:
Substances chimiques
Immunosuppressive Agents
0
RNA, Viral
0
Fingolimod Hydrochloride
G926EC510T
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
546-549Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
J Neuroimmunol. 2020 Aug 15;345:577282
pubmed: 32505908
Mult Scler Relat Disord. 2020 Jul;42:102182
pubmed: 32416330
Neurologia (Engl Ed). 2020 Apr;35(3):170-175
pubmed: 32299636
Mult Scler Relat Disord. 2020 Jun;41:102135
pubmed: 32339915
JAMA Neurol. 2016 Jul 1;73(7):790-4
pubmed: 27135594
Neurol Neuroimmunol Neuroinflamm. 2020 May 5;7(4):
pubmed: 32371550
J Med Virol. 2020 Nov;92(11):2260-2262
pubmed: 32462717
Brain Behav Immun. 2015 Nov;50:78-86
pubmed: 26130058
JAMA Neurol. 2016 Nov 1;73(11):1375
pubmed: 27669336
Mult Scler Relat Disord. 2017 Jul;15:A1-A2
pubmed: 28641776
J Med Virol. 2021 Jan;93(1):546-549
pubmed: 32644205
BMJ. 2020 Jul 3;370:m2648
pubmed: 32620554
Science. 1980 Aug 22;209(4459):933-4
pubmed: 7403860
Mult Scler Relat Disord. 2020 Sep;44:102297
pubmed: 32554284
Mult Scler Relat Disord. 2020 Apr;39:102073
pubmed: 32334820
JAMA Neurol. 2016 Jul 1;73(7):775-6
pubmed: 27136400
Mult Scler Relat Disord. 2020 Aug;43:102174
pubmed: 32464584
Mult Scler Relat Disord. 2020 Jul;42:102185
pubmed: 32408147
Mult Scler Relat Disord. 2020 Jul;42:102180
pubmed: 32408155
JAMA Neurol. 2016 Nov 1;73(11):1375-1376
pubmed: 27669463